federal_register: 2012-30274

All Federal Register documents (rules, proposed rules, notices, presidential documents) from 1994 to present. Nearly 1M documents with full-text search.

This data as json

document_number title type abstract publication_date pub_year pub_month html_url pdf_url agency_names agency_ids excerpts
2012-30274 Draft Guidance for Industry on Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products; Availability Notice The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled "Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products." The purpose of this document is to provide guidance to industry on enrichment strategies that can be used in clinical trials intended to support effectiveness and safety claims in new drug applications (NDAs) and biologics license applications (BLAs). This document defines several types of enrichment strategies, provides examples of various potential clinical trial designs, and discusses potential regulatory considerations when using enrichment strategies in clinical trials. 2012-12-17 2012 12 https://www.federalregister.gov/documents/2012/12/17/2012-30274/draft-guidance-for-industry-on-enrichment-strategies-for-clinical-trials-to-support-approval-of https://www.govinfo.gov/content/pkg/FR-2012-12-17/pdf/2012-30274.pdf Health and Human Services Department; Food and Drug Administration 221,199 The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled "Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products." The purpose of this document is to...

Links from other tables